Pfizer’ s BRAFTOVI* Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer #ASCO26
Pfizer announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (ERBITUX®) and FOLFIRI…
Thymidine Kinase 2 Deficiency (TK2d): European Commission approves doxecitine and doxribtimine (KYGEVVI®) as first and only treatment
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for KYGEVVI (doxecitine and doxribtimine) for the treatment…
Evolving antibiotic resistance under pressure
The bacteria Acinetobacter baumannii (A. baumannii) is a haunting presence in many hospitals in the United States, where more than one in 100 patients are treated for A. baumannii infections.…
AI Tool Uses Face Photos to Estimate Biological Age and Predict Cancer Outcomes
Eyes may be the window to the soul, but a person’s biological age could be reflected in their facial characteristics. Investigators from Mass General Brigham developed a deep learning algorithm…
Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group of Women with Early-Stage Disease #ESMO24
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial (1) and cervical cancers (2) who gain clinically meaningful benefit from adding immunotherapy to current standard treatments,…
Long-term results from Testicular Cancer treatment are positive
A new study shows that by combining different chemotherapy drugs, testicular cancer remains highly treatable and often curable, even after first-line treatment fails. . The recent study published in the…
Linfoma, novita’ terapie Roche al Congresso dell’Associazione Europea di Ematologia #EHA24
Roche ha annunciato risultati statisticamente e clinicamente significativi dello studio di Fase III STARGLO relativi alla combinazione glofitamab + gemcitabina e oxaliplatino (GemOx) rispetto alla combinazione rituximab e GemOX, nei…
Gene therapy is halting cancer. Can it work against brain tumors?
Grant of up to $11 million will fund a clinical trial at UCSF that uses a smarter new CAR-T guided by precision technology. A type of gene therapy called CAR-T…